Pf Prism CV

Pf Prism CV is a key subsidiary of Pfizer, a global biopharmaceutical leader focused on the discovery, development, and commercialization of innovative medicines and vaccines. The entity is frequently involved in the management of Pfizer's international intellectual property and strategic licensing agreements across various therapeutic areas, including oncology, immunology, and cardiology. Pfizer's broader portfolio includes high-impact treatments such as the CDK4/6 inhibitor Ibrance, the anticoagulant Eliquis, and the COVID-19 vaccine Comirnaty. The company maintains a robust pipeline with a significant focus on mRNA technology, protein degradation, and next-generation oncology therapies. Pfizer's recent acquisition of Seagen further strengthens its position in the antibody-drug conjugate (ADC) space.